| 02nd week of 2009 patent applcation highlights part 37 |
| Patent application number | Title | Published |
|---|
| 20090010910 | COMPOSITIONS AND METHODS FOR DERMATOLOGICAL WOUND HEALING - The invention relates to compositions for debriding damaged skin comprising at least one enzymatic debriding agent and at least one antiseptic compound comprising heavy metal ions. The present invention further relates to kit and methods for topical debridement of damaged skin, particularly of burned skin. | 2009-01-08 |
| 20090010911 | METHODS AND COMPOSITIONS FOR AFFECTING CYCLOPHILIN A REGULATION OF KINASES IN MODULATING CELLULAR ACTIVITIES - The present invention relates to drug screening assays, therapeutic protocols and pharmaceutical compositions designed to target non-receptor tyrosine family kinases and components of the tyrosine kinase family signal transduction pathways. It has been previously reported by the inventors that a substrate SH2 domain docking mechanism apart from the kinase active site is required for appropriate tyrosine phosphorylation by these tyrosine kinases. According to the invention, it has been discovered that Cyclophilin A, the target of drugs such as cyclosporin A, mediates its regulatory effects by interacting with this remote SH2 domain, making modulation of this interaction possible for regulation and improved therapeutic intervention. | 2009-01-08 |
| 20090010912 | Use of Alkaline Phosphatase for the Detoxification of Lps Present at Mucosal Barriers - The present invention provides a use for alkaline phosphatase for the manufacture of a medicament for the prevention or reduction of toxic LPS influx through a mucosal lining of a mammalian body cavity. A source of alkaline phosphatase is administered for the prophylaxis or treatment of LPS mediated or exacerbated diseases. The invention also provides compositions comprising a source of alkaline phosphatase for the prevention or reduction of (toxic) LPS influx or passage through mucosal layers. | 2009-01-08 |
| 20090010913 | NATURAL LINIMENT FOR TREATMENT OF SKIN CANCERS - A liniment composition for reversing or retarding the growth of cancerous skin tumors comprising primarily, pancreatin, pepsin, betaine HCL, emulsified vitamin A, and zinc, pancrelipase, fenugreek, papain, amylase and ox bile extract, with optional trace amounts of other ingredients. | 2009-01-08 |
| 20090010914 | Use of Oligouronates for Treating Mucus Hyperviscosity - The invention provides a method of treatment of a human or non-human subject to combat mucosal hyperviscosity in the respiratory tract, which method comprises application to a mucosal surface in said tract in said subject of an effective amount of a physiologically tolerable oligouronate. | 2009-01-08 |
| 20090010915 | Methods for Conducting Metabolic Analyses - The present invention provides methods and apparatus for purifying metabolites of interest and conducting metabolic analyses. The methods generally involve determining metabolic flux values for a plurality of target analytes by monitoring the relative isotope abundance of a stable isotope in a substrate labeled with the stable isotope and/or one or more target metabolites formed through metabolism of the labeled substrate. Certain methods utilize multiple electrophoretic methods to separate the target analytes from other components within the sample being analyzed. The methods can be used in a variety of applications including screens to identify metabolites that are correlated with certain diseases and diagnostic screens for identifying individuals having, or susceptible to, a disease. | 2009-01-08 |
| 20090010916 | C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis - A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous conversion to tcuPA in blood at therapeutic concentrations. Two-chain M5 was shown to form complexes with C1-inhibitor, which was the principal inhibitor of tcM5 in plasma. The effect of supplemental additions of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restored the stability of high-dose M5 and prevented fibrinogenolysis but not fibrinolysis, the rate of which was not compromised by the inhibitor. Due to higher dose tolerance of M5 in the presence of supplemental C1-inhibitor, the rate of fibrin-specific lysis reached that achievable by nonspecific fibrinolysis, which is the maximum possible for a plasminogen activator. Plasma C1-inhibitor stabilized M5 in plasma by inhibiting tcM5 which would otherwise greatly amplify non-specific plasminogen activation causing more tcM5 generation from M5. This unusual dissociation of inhibitory effects, whereby fibrinogenolysis and not fibrinolysis is inhibited, has significant implications for improving the safety and efficacy of fibrinolysis. Methods of reducing bleeding and non-specific plasminogen activation during fibrinolysis by administering M5 along with exogenous C1-inhibitor are disclosed. | 2009-01-08 |
| 20090010917 | Therapeutic Agents Comprising Pro-Apoptotic Proteins - The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax. | 2009-01-08 |
| 20090010918 | METHODS FOR TREATMENT USING COLLAGENASE - Methods for treatment by collagenase injections are provided, which are effective in dissolving and lysing a collagenase septa network to treat carpal tunnel, plantar fasciitis and lateral epicondylitis conditions. The methods treat such conditions by injecting or otherwise delivering purified collagenase to the afflicted region of the patient, as well as use of collagenase for manufacture of a medicament for such conditions. | 2009-01-08 |
| 20090010919 | Diagnostics and Therapeutics for Diseases Associated With Fibroblast Activation Protein (Fap) - The invention provides a human FAP which is associated with the cardiovascular diseases, respiratory diseases, cancer, dermatological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases and endocrinological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, respiratory diseases, cancer, dermatological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases and endocrinological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of FAP as well as pharmaceutical compositions comprising such compounds. | 2009-01-08 |
| 20090010920 | Fc Variants Having Decreased Affinity for FcyRIIb - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 2009-01-08 |
| 20090010921 | Antigen binding molecules with increased Fc receptor binding affinity and effector function - The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. | 2009-01-08 |
| 20090010922 | COMPOSITIONS AND METHODS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P. | 2009-01-08 |
| 20090010923 | TREATMENT OF CANCER WITH ANTI-MUSCARINIC RECEPTOR AGENTS - The present invention relates to methods of treating proliferative disorders of colon cells. The methods comprise administering to the cells an effective amount of at least one agent to reduce M3 muscarinic receptor-mediated transactivation of at least one epidermal growth factor receptor. | 2009-01-08 |
| 20090010924 | Apoptotic Anti-IgE Antibodies - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 2009-01-08 |
| 20090010925 | ANTIBODY VARIANTS - Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen. | 2009-01-08 |
| 20090010926 | Extended Treatment of Multiple Sclerosis - Methods for extended treatment of multiple sclerosis are described. | 2009-01-08 |
| 20090010927 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells - The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders. | 2009-01-08 |
| 20090010928 | Anti-anthrax antibody, formulations thereof, and methods of use - The present invention provides an antibody which binds to | 2009-01-08 |
| 20090010929 | Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates - The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A | 2009-01-08 |
| 20090010930 | ANTIBODIES TO VLA-1 - Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures. | 2009-01-08 |
| 20090010931 | COMPOSITIONS AND METHODS FOR RESTORING SENSITIVITY TO TREATMENT WITH HER2 ANTAGONISTS - Methods and compositions for restoring growth inhibition sensitivity to a tumor cell resistant to growth inhibition by HER2 antagonists. The methods involve administering a PCDGF antagonist to the cell in an amount effective to stimulate or restore growth inhibition sensitivity to HER2 antagonists. The invention also provides treatment regimens, and therapeutic compositions comprising an HER2 antagonist and a PCDGF antagonist. | 2009-01-08 |
| 20090010932 | GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV - GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections. | 2009-01-08 |
| 20090010933 | METHODS FOR USING CHIMERIC VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR PROTEINS - The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and anglogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization. | 2009-01-08 |
| 20090010934 | CELL LINES, LIGANDS AND ANTIBODY FRAGMENTS FOR USE IN PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND TREATING HAEMOSTASIS DISORDERS - A ligand derived from, e.g., a Fab fragment of a monoclonal antibody obtainable from the cell line deposited with the Belgian Coordinated Collections of Micro-Organisms under accession number LMBP 5108CB binds to the human platelet glycoprotein GPIb and prevents the binding of von Willebrand factor to said GPIb without inducing thrombocytopenia. The said ligand is useful, in admixture with a pharmaceutically acceptable carrier, in a pharmaceutical composition, optionally further comprising a thrombolytic agent, for preventing and/or treating haemostasis disorders. | 2009-01-08 |
| 20090010935 | Compositions and Methods of Treating Tumors - Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed. | 2009-01-08 |
| 20090010936 | Novel Stra6 Polypeptides - The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 2009-01-08 |
| 20090010937 | Membrane Attack Complexes Associated with Circulating Immune Complexes - The invention relates to demonstrate the presence of non covalently linked complement proteins with CIC. Invention demonstrate the presence of C5 and MAC on CIC. The invention provides methods to measure M complement proteins C1q, C3, C4, C5 bound to CIC as markers of disease activity and pathogenicity for complement and CIC mediated diseases. The invention also relates to modifications and blocking of formation of MAC on the CIC by developing a useful reagent that can be monoclonal antibody, active molecule, mimotope or peptide molecule. The invention describes usefulness to reduce the non-covalent complement components, formation of MAC and association of C5 to CIC for therapeutic application in pathological disease with involvement of CIC and complement. | 2009-01-08 |
| 20090010938 | SHORT IMMUNOMODULATORY OLIGONUCLEOTIDES - The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines. | 2009-01-08 |
| 20090010939 | IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS - The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection. | 2009-01-08 |
| 20090010940 | Parathyroid Hormone Analogues and Methods of Use - The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects. | 2009-01-08 |
| 20090010941 | Methods for treating HIV - The invention relates to methods of treating HIV by administering a TRAIL receptor activator. The invention also relates to methods for inducing apoptosis in an HIV reservoir cell by contacting the cell with TRAIL receptor activator such as an M-CSF effector kinase inhibitor. | 2009-01-08 |
| 20090010942 | NOVEL PRIMATE CHITINASES AND USES THEREFOR - Novel primate chitinases (pNC) and nucleic acids encoding these chitinases are disclosed. The pNCs of the invention are homologous to human acidic mammalian chitinases (hAMCase) and human chitotriosidase, in terms of their exon/intron genomic structure and conserved catalytic sites. The polypeptides and nucleic acids of the invention can be used to develop, and/or screen for, modulators of chitinase-activities, e.g., antisense, antibodies, RNAi. The modulators identified using methods and reagents disclosed herein can be used to reduce chitinase-associated inflammatory conditions. | 2009-01-08 |
| 20090010943 | Peptides associated with HLA-DR MHC class II molecule and involved in Rheumatoid arthritis - Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are citrullinated antigenic peptides having an increased affinity for HLA-DR molecules and associated with Rheumatoid Arthritis. These novel peptides provide the basis for new methods of diagnosis and treatment of Rheumatoid Arthritis. | 2009-01-08 |
| 20090010944 | OLIGOSIALIC ACID DERIVATIVES, METHODS OF MANUFACTURE, AND IMMUNOLOGICAL USES - The invention relates to methods of producing, and compositions comprising, an isolated alpha (2→8) or (2→9) oligosialic acid derivative bearing a non-reducing end enriched for one or more de-N-acetyl residues and resistant to degradation by exoneuraminidase. A representative production method involves: (i) treating an alpha (2→8) or (2→9) oligosialic acid precursor having a reducing end and a non-reducing end with sodium borohydride under conditions for de-N-acetylating the non-reducing end; and (ii) isolating alpha (2→8) or (2→9) oligosialic acid derivative having one or more de-N-acetylated residues and a non-reducing end that is resistant to degradation by exoneuraminidase. Isolated alpha (2→8) or (2→9) oligosialic acid derivatives that comprise a non-reducing end de-N-acetyl residue are provided, as well as antibodies specific for the derivatives, compositions comprising the derivatives, kits, and methods of use including protection against and detection of | 2009-01-08 |
| 20090010945 | Partially Loaded Antibodies And Methods Of Their Conjugation - A protein containing one or more activatable groups, e.g., an antibody, is subjected to partial or complete reduction of one or more such bonds to form reactive groups; the resulting protein is reacted with a drug which is reactive with some of the reactive groups, such as certain radiometals, chelating agents, and toxins, so as to form a conjugate useful in, e.g., in vitro diagnosis, in vivo imaging, and therapy. | 2009-01-08 |
| 20090010946 | Novel Stromal Cell-Derived Factor-1 Polypeptides, Polynucleotides, Modulators Thereof and Methods of Use - Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases. | 2009-01-08 |
| 20090010947 | Red Microalgae Expressing Exogenous Polypeptides And Methods Of Generating And Utilizing Same - A method of transforming red microalgae is provided. The method is effected by: (i) culturing red microalgae cells under predetermined light/dilution conditions to thereby generate competent red microalgae cells; and (ii) introducing at least one exogenous polynucleotide into said competent red microalgae cells, thereby transforming the red microalgae. | 2009-01-08 |
| 20090010948 | ANTI-TUMOR VACCINES DELIVERED BY DENDRITIC CELLS DEVOID OF INTERLEUKIN-10 - It has been discovered that reducing, inhibiting or preventing the expression of immunosuppressive cytokines or tolergenic agents in antigen presenting cells improves the ability of the antigen presenting cell to promote an immune response. One embodiment provides a genetically engineered antigen presenting cell that has reduced or no expression of IL-10. Preferred antigen presenting cells are dendritic cells. Expression of IL-10 can be inhibited or blocked by genetically engineering the antigen presenting cell to express inhibitory nucleic acids that inhibit or prevent the expression mRNA encoding immunosuppressive cytokines. Inhibitory nucleic acids include siRNA, antisense RNA, antisense DNA, microRNA, and enzymatic nucleic acids that target mRNA encoding immunosuppressive cytokines. Immunosuppressive cytokines include, but are not limited to IL-10, TGF-β, IL-27, IL-35, or combinations thereof. Tolerogenic agents include but are not limited to indoleamine 2,3-dioxygenase. | 2009-01-08 |
| 20090010949 | POLYSIALIC ACID DERIVATIVES, METHODS OF PRODUCTION, AND USES IN ENHANCING CANCER ANTIGEN PRODUCTION AND TARGETING - The present invention relates to compositions and methods of their production and use, including use in increasing de-N-acetyl sialic acid antigen of a mammalian cell and methods that exploit the increase in deNAc sialic acid antigen on such cells. | 2009-01-08 |
| 20090010950 | EX-VIVO ISOLATED CD25+CD4+ T CELLS WITH IMMUNOSUPPRESSIVE ACTIVITY AND USES THEREOF - Ex-vivo isolated human CD25 | 2009-01-08 |
| 20090010951 | Epitope/Peptide Recognized By Hla-A2402-Restricted Ep/Cam-Specific Ctl And Use Of The Same - A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402. | 2009-01-08 |
| 20090010952 | PHARMACEUTICAL COMPOUND FOR EFFECTING LOCALIZED, NON-SYSTEMIC AND SYSTEMIC, IMMUNOGENIC TREATMENT OF CANCER USING CRT OR ERP57 TRANSLOCATION - Anthracyclines-treated tumor cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclines induce the rapid, pre-apoptotic translocation of calreticulin (CRT) and/or ERP57 to the cell surface. Knock down of CRT and/or ERP57 suppressed the phagocytosis of anthracyclines-treated tumor cells by dendritic cells and abolished their immunogenicity in mammals, such as mice. The anthracyclines-induced CRT and/or ERP57 translocation was mimicked by inhibition of the protein phosphatase1/GADD34 complex. Administration of recombinant colreticulin, and not recombinant ERP57, or inhibitors of protein phosphatase1/GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo. These data identify calreticulin and/or ERP57 as a key feature determining anti-cancer immune responses and delineate a possible strategy for immunogenic chemotherapy. | 2009-01-08 |
| 20090010953 | PEPTIDES OF A MELANOMA ANTIGEN AND THEIR USE IN DIAGNOSTIC, PROPHYLACTIC, AND THERAPEUTIC METHODS - Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma. | 2009-01-08 |
| 20090010954 | PREVENTION AND TREATMENT OF SUB-CLINICAL PCVD - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs. | 2009-01-08 |
| 20090010955 | Vaccines Containing Canine Parvovirus Genetic Variants - Canine parvovirus vaccines and diagnostics and methods for their use are provided. The vaccines are effective against emerging dominant canine parvovirus variants. | 2009-01-08 |
| 20090010956 | EHRLICHIA EWINGII PROTEINS, NUCLEIC ACIDS, AND METHODS OF THEIR USE - The novel omp-1 gene cluster encoding twenty one | 2009-01-08 |
| 20090010957 | Immunogenic Mycoplasma Hyopneumoniae Polypeptides - polypeptides and nucleic acids, as well as nucleic acid expression vectors and host cells containing nucleic acid vectors are provided. In addition, compositions containing | 2009-01-08 |
| 20090010958 | Compositions effective in altering the perception of malodor - A method of modifying perception of a malodor, such as the stench associated with putrefying flesh, by selectively affecting specific olfactory receptors in an individual is disclosed. Disclosed are articles of manufacture and especially innovative compositions effective in implementing the method of the present invention including at least three plant extracts. | 2009-01-08 |
| 20090010959 | Pneumococcal Polysaccharide Conjugate Vaccine - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 2009-01-08 |
| 20090010960 | Bacteriophage-mediated immunisation against hepatitis - The present invention relates to vaccines comprising a bacteriophage which has been engineered to express an immunogenic protein/peptide and wherein the surface of the bacteriophage has not been modified to contain proteins/peptides designed to target the phage to receptors on the surface of specific cell types. | 2009-01-08 |
| 20090010961 | Avirulent, immunogenic flavivirus chimeras - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second | 2009-01-08 |
| 20090010962 | Genetically Engineered Swine Influenza Virus and Uses Thereof - The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations. | 2009-01-08 |
| 20090010963 | Raccoon Poxvirus Expressing Rabies Glycoproteins - The present invention relates to recombinant raccoon poxvirus vectors that express the rabies virus glycoprotein gene at the hemagglutinin (ha) locus of the poxvirus genome or express the glycoprotein gene of the same or different rabies strains at the thymidine kinase (tk) and the hemagglutinin (ha) loci of the poxvirus genome, and their use as adjuvant-free vaccines. The raccoon poxvirus vector comprises the nucleic acid molecules encoding the glycoprotein of a Challenge Virus Standard rabies strain inserted and expressed at the tk locus of the poxvirus genome and of a Pasteur-Paris rabies strain inserted and expressed at the ha locus of the poxvirus genome. The vaccine may optionally contain a mixture of additional feline and canine antigens for immunization of animals. Also disclosed are methods for inducing an immune response to rabies in a mammal by administering to the mammal an effective immunizing amount of the vaccine of the invention. | 2009-01-08 |
| 20090010964 | Lipid and Nitrous Oxide Combination as Adjuvant for the Enhancement of the Efficacy of Vaccines - The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5ω3], decosahexaenoic acid [C22: 6ω3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide. | 2009-01-08 |
| 20090010965 | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin - The present invention provides a method for providing a muscle relaxant, wherein said muscle relaxant is a reconstituted solution comprising the neurotoxic component of botulinum toxin free of complexing proteins, which exhibits at least one of the following characteristics, more preferably all characteristics a) to d):
| 2009-01-08 |
| 20090010966 | MODIFIED DIPHTHERIA TOXINS - The present application relates to compositions of modified diphtheria toxin and fusion proteins containing modified diphtheria toxin that reduce binding to vascular endothelium or vascular endothelial cells, and therefore, reduce the incidence of Vascular Leak Syndrome, as well as methods of making the compositions. The present application also relates to a polypeptide toxophore from a modified diphtheria toxin, where the modification is at least one amino acid residue at the amino acid residues 6-8, 28-30 or 289-291 of an unmodified native diphtheria toxin. Also described are fusion proteins which contain a modified diphtheria toxin and a non-diphtheria toxin fragment which contains a cell binding portion. The modified diphtheria toxins described can be used for the treatment of a malignant disease or a non-malignant disease. | 2009-01-08 |
| 20090010967 | CLOSTRIDIAL TOXIN DERIVATIVES AND METHODS FOR TREATING PAIN - Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds. | 2009-01-08 |
| 20090010968 | Spot-on formulation useful for cosmetology and dermatology - The invention relates to a novel formulation of use in cosmetology and in dermatology which uses the storage capacity of the sebaceous glands. | 2009-01-08 |
| 20090010969 | Methods And Materials For Skin Care - The invention provides a cosmetic method for, preventing, minimizing and removing wrinkles and providing for smoother and more robust skin surfaces comprising applying a material incorporating water-insoluble copper compounds which release Cu | 2009-01-08 |
| 20090010970 | DISSOLVABLE TOOTH WHITENING STRIP - The present invention provides a dissolvable strip for whitening teeth. The strip, which is preferably a single layer, has a whitening agent and a water-soluble or water dispersible polymer system. The dissolution of the whitening composition is controlled by interaction of the whitening composition with an oral environment containing saliva. The present invention further provides a process for preparing the whitening strip in the form of a dry film and a method of whitening teeth. | 2009-01-08 |
| 20090010971 | Disintegratable Zinc Oxide Powder and Method For Producing the Same - The method for producing a disintegratable zinc oxide powder of the present invention is characterized by comprising: neutralizing an aqueous solution containing a water-soluble zinc salt and a carboxylic acid or an aqueous solution containing a water-soluble zinc carboxylate with an alkali carbonate to produce precipitate; and firing the precipitate to obtain zinc oxide powder. As a water-soluble zinc salt, zinc chloride or zinc acetate is preferably used. As an acid, acetic acid is preferably used. As an alkali carbonate, sodium carbonate is preferably used. The disintegratable zinc oxide powder has the morphology in which the primary particles of zinc oxide are aggregated to form secondary particles, and these secondary particles are further aggregated to form the zinc oxide powder. The powder can achieve excellent UV protection capability, excellent transparency, and excellent feeling in use through its disintegration. Also, it has good usability and good handling properties. | 2009-01-08 |
| 20090010972 | DEODORANT COMPOSITIONS - Deodorant compositions comprising an emulsion including a continuous polar solvent phase and a discontinuous oil phase are provided. The oil phase contains a water insoluble oil ingredient and a fragrance composition, each of which are chosen such that at least some of the fragrance components preferentially associate with the oil ingredient within the emulsion to provide an improved scent expression profile. | 2009-01-08 |
| 20090010973 | Silicas - An amorphous precipitated silica with controlled abrasivity and effective cleaning properties for use in an oral composition produced through comminution and classification of the silica to form particles with an oil absorption value of 150 cm | 2009-01-08 |
| 20090010974 | Alcohol-In-Oil Type Emulsion Comprising a Multivalent Metal Salt - The present invention relates to emulsion science, especially within the area of alcohol-in-oil type emulsion, where the level of ions comprised in the alcohol-in-oil type emulsion is relatively high. In particular, the invention relates to a stable alcohol-in-oil type emulsion comprising a multivalent metal salt that may act as an antiperspirant. | 2009-01-08 |
| 20090010975 | Non-transparent composition for film - The present invention provides a non-transparent film composition that has light-shielding properties and can thereby maintain the stability and quality of products, such as formulations, for a long period of time; and formulations using this film composition, and particularly filled capsules. The non-transparent film composition contains a water-soluble metal compound containing at least one metal selected from the group consisting of sodium, potassium, calcium, magnesium, aluminium, manganese, iron, cobalt, nickel, copper, strontium, and barium; and a water-soluble cellulose derivative. The non-transparent film composition is preferably prepared by: spreading an aqueous solution containing a water-soluble cellulose derivative and a water-soluble metal compound containing a monovalent, divalent or trivalent metal into a film- or sheet-like form; and heating the solution at a temperature of 60° C. or higher to obtain the film composition by drying and solidification. | 2009-01-08 |
| 20090010976 | Cosmetic or dermopharmaceutical compositions containing kombucha - Cosmetic or dermopharmaceutical compositions which contain kombucha are disclosed. The present invention further relates to the use of kombucha and cosmetic or dermopharmaceutical compositions containing the same, alone or in combination, for the care of the skin, mucosae and skin appendages, and in particular for preventing the signs of endogenous and/or exogenous ageing. | 2009-01-08 |
| 20090010977 | Insect repellant fabrics having nanocapsules with insecticide - The present invention relates to method of manufacturing a prytheroid-treated fabric and manufactured products created thereby. Through the development and application of prytheroid nanocapsules to a fabric, the fabric exhibits insecticidal properties, even following successive washings and solar exposure. | 2009-01-08 |
| 20090010978 | Green tea jewelry - A method for making green tea jewelry is provided. The jewelry may be worn as a transdermal source of green tea components used as an alternative to or in addition to ingestion of green tea liquid or solids. Also provided is a kit for providing green tea jewelry in a substantially water resistant and air-tight package. The kit may comprise additional articles such as informational inserts and scents. | 2009-01-08 |
| 20090010979 | Method of Controlling Termites - The present invention provides a method of controlling termites and other social insects by treating a locus which locus comprises a location treated by termiticide and a location treated by a termite attractant composition. | 2009-01-08 |
| 20090010980 | Materials coatings and methods for self-cleaning and self-decontamination of metal surface - A composite structure exhibiting the ability to degrade chemical or biological agents upon contact comprising a substrate to be protected from the deleterious effects of chemical or biological agents possessing surface groups capable of deactivating materials having the ability to degrade chemical or biological agents, a buffer film, coated onto the substrate, that blocks the ability of the substrate surface groups to deactivate the materials having the ability to degrade chemical or biological agents, and a protective film, coated onto the buffer film, containing materials having the ability to degrade chemical or biological agents encapsulated in or comprising the outer surface of the protective film. | 2009-01-08 |
| 20090010981 | ANTIMICROBIAL MATERIAL FOR IMPLANTING IN BONES - The invention relates to an antimicrobial material and method for inhibiting bacterial growth. The antimicrobial material may be used for implanting in bones and for coating or producing an implant or an implantable medical device, whereby particles formed from an antimicrobial material are remotely dispersed inside a matrix material that forms a matrix when hardened. In order to improve the compatibility of the antimicrobial material, the invention provides that the metal is formed from aggregates of primary particles having an average particle size ranging from 10 to 100 nm. | 2009-01-08 |
| 20090010982 | BIOCOMPATIBLE ADHERENT SHEET FOR TISSUE SEALING - A biocompatible adherent sheet for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The biocompatible adherent sheet includes a carrier sheet including a biocompatible polymer and a modified chitosan evenly disposed on one or both sides of the carrier sheet. Methods of preparing a biocompatible adherent sheet and methods of using a biocompatible adherent sheet are also provided. The biocompatible adherent sheet may also include a bioactive agent. | 2009-01-08 |
| 20090010983 | Alginate Coated, Polysaccharide Gel-Containing Foam Composite, Preparative Methods, and Uses Thereof - The invention relates to composites comprising a polysaccharide gelled within pores of a foam and an polysaccharide coating, methods of preparation, and uses thereof, for example, in biomedical applications such as cell culture media and implants, controlled release delivery systems, food applications, industrial applications, and personal care applications such as cosmetic and oral hygiene. | 2009-01-08 |
| 20090010984 | STEROID LIPID-MODIFIED POLYURETHANE AS AN IMPLANTABLE BIOMATERIAL, THE PREPARATION AND USES THEREOF - A modified polyurethane including a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of the modified polyurethane, methods of preparing modified polyurethanes and the use thereof as an implantable biomaterial. | 2009-01-08 |
| 20090010985 | Article with Lubricated Surface and Method - Articles having reduced sliding frictional force comprising a lubricant applied to one or more surfaces of the article, and the lubricant-coated surface treated by exposing the surface to an energy source, wherein the energy source is an ionizing gas plasma at about atmospheric pressure. The ionizing gas plasma may be a flame plasma. One or more of the surfaces may be exposed to the ionizing gas plasma at about atmospheric pressure prior to application of the lubricant. | 2009-01-08 |
| 20090010986 | Polymeric gel delivery system for pharmaceuticals - Implantable, injectable, insertable, or otherwise administrable compositions that form hydrogels when implanted, injected, inserted, or administered into or onto living tissues comprise a pharmaceutically effective compound wherein the pharmaceutically effective compound is a codrug, or pharmaceutically acceptable salt or prodrug thereof in admixture with a hydrogel-forming compound. The pharmaceutically effective compound may be any compound that is soluble in bodily fluids, or that forms bodily fluid-soluble adducts when exposed to bodily fluids. Exemplary compounds include analgesic, anti-inflammatory and antibiotic compounds. The hydrogel-forming compound is a biologically tolerated substance that forms a hydrogel upon exposure to bodily fluids, such as the interstitial fluid surrounding or within a joint. | 2009-01-08 |
| 20090010987 | Methods and Devices for Reducing Tissue Damage After Ischemic Injury - Methods and devices are provided for the local delivery of anti-ischemic agents which reduce myocardial tissue damage due to ischemia or reperfusion, in combination with compounds that sensitize the response of the tissue to the anti-ischemic agent. The therapeutic agents are delivered to the myocardial tissue over an administration period sufficient to achieve reduction in ischemic or reperfusion injury of the tissue. | 2009-01-08 |
| 20090010988 | COMPOSITION OF BONE FORMATION WITH PHSRN-RGD CONTAINING OLIGOPEPTIDE - A PHSRN-RGD-containing oligopeptide and a composition for promoting bone formation, which contains such oligopeptide as an effective ingredient. The oligopeptide promotes osteoblastic cell adhesion and differentiation and enhances bone regenerative ability, so that the inventive oligopeptide can be effectively used in regenerative treatment of bone tissue and periodontal tissue. | 2009-01-08 |
| 20090010989 | Coating For Implants and Implants With Improved Osteointegration, and Manufacturing Method - A coating on an implant, said implant being intended for implantation in/on an implantation area, is provided. The coating comprises nitric oxide (NO) for obtaining an anti-viral, anti-fungal, and anti-bacterial effect, and for promotion of osteo-integration of the implant, bone healing, bone growth, and wound healing at said implantation area. A nitric oxide (NO) eluting polymer is integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of a therapeutic dosage of nitric oxide (NO). An implant and a kit of implants, comprising said coating are also provided. Furthermore, a manufacturing method for the implant is disclosed. | 2009-01-08 |
| 20090010990 | Process for depositing calcium phosphate therapeutic coatings with controlled release rates and a prosthesis coated via the process - A method of coating a substrate wherein the crystallinity of a calcium phosphate substance in a coating material is controlled, the calcium phosphate substance is loaded with a therapeutic agent, and the loaded calcium phosphate is deposited onto at least a portion of the substrate. | 2009-01-08 |
| 20090010991 | Nasal Passage Stent - A drug coated nasal stent implant that provides filtration of environmental pollutants and airborne allergens from inhaled air regulating the air before it is ingested into the remainder of the respiratory tract. The coatings include but are not limited to a variety of allergenic-specific antigen targeted antibodies as well as anti-inflammatory drugs such as antihistamines | 2009-01-08 |
| 20090010992 | Drug formulations for oral transmucosal delivery to pediatric patients - Improved compositions, methods and systems for oral transmucosal administration of small volume bioadhesive drug dosage forms to pediatric subjects are provided. The drug dosage form is easily administered and may be delivered using a single dose applicator or a device. | 2009-01-08 |
| 20090010993 | Composition comprising polyphenol - A food product, being a spread comprising from 10-85 wt % of fat or a dairy based drink comprising from 0.05 to 1 wt % of kaempferol can advantageously be used to control blood pressure. Specifically kaempferol may be used for vasorelaxation. | 2009-01-08 |
| 20090010994 | Wound Dressing Comprising an Anti-Inflammatory Pain-Killing Agent and a Complex of Silver Ion and a Transitional Element of Group IV of the Periodic System of Elements - A wound dressing comprising one or more absorbent elements capable of absorbing wound exudates, a non-steroid anti-inflammatory pain-killing agent and a complex of silver ion and a transitional element of group IV of the periodic system of elements. | 2009-01-08 |
| 20090010995 | Patch and patch preparation - The present invention aims to provide a patch and a patch preparation that do not require an acrylic polymer, and are capable of maintaining a large amount of an organic liquid component in an adhesive layer. | 2009-01-08 |
| 20090010996 | Human antibiotic proteins - The invention relates to proteins, notably SAP-2 and SAP-3, having an antibiotic action. The invention also relates to a method for purifying certain antimicrobial proteins, as well as to a use of said antimicrobial proteins for antibiotic therapy or to a use of cells which were transfected with a DNA which codes for the proteins provided for in the invention | 2009-01-08 |
| 20090010997 | Multi-layer medical patch with impermeable center - A muco-adhesive patch for delivery of drugs into mucous membranes. On the muco-contact side, a water impermeable layer covers the center of the patch and less than half of the muco-contact side of the patch. Drugs may be added by mixing the drug with an adhesive material and placing a spot of the drug plus adhesive onto the exposed side of the water impermeable layer. A lenticular medical patch with a thin, tapered edge can be made with multiple layers by passing a single sheet such as a sheet of plastic through a production line in which each layer is applied in turn maintaining registration by reference to edges of the sheet or to marks on the sheet. | 2009-01-08 |
| 20090010998 | Drug-delivery patch comprising a dissolvable layer and uses thereof - The present invention provides a drug-delivery patch having at least one dissolvable layer comprising an active material and an adhesive backing or cover. The present invention also provides a method of transdermally vaccinating an animal by ablating an area of the stratum corneum of the animal and applying the patch described herein to the area. | 2009-01-08 |
| 20090010999 | Complex Particles and Coated Complex Particles - The present invention provides, for example, a method of inhibiting aggregation of complex particles in which a drug is adhered to lead particles, characterized by containing a lipid derivative or a fatty acid derivative of one or more substance(s) selected from sugars, peptides, nucleic acids and water-soluble polymers or a surfactant in the lead particles. Further, it provides, for example, a method of producing the complex particles in which a nucleic acid as a drug or a drug is adhered to lead particles, comprising the step of dispersing or dissolving the nucleic acid as a drug or the drug and an adhesion-competitive agent so as to be contained in a liquid in which the lead particles containing a lipid derivative or a fatty acid derivative of one or more substance(s) selected from sugars, peptides, nucleic acids and water-soluble polymers or a surfactant are dispersed, thereby allowing the nucleic acid as a drug or the drug and the adhesion-competitive agent adhered to the lead particles. | 2009-01-08 |
| 20090011000 | Inhibitors of Infection - Fusion inhibitor peptides are provided comprising a sequence derived from an HR2 domain. In preferred embodiments, the peptides are capable of oligomerization. Also provided are nucleic acids encoding the peptides, vectors comprising the nucleic acids and host cells transformed with the vectors. The peptides may be used as medicaments. Also provided are methods for expressing a protein comprising one or more transmembrane domain(s) in an expression system. The methods comprise fusing a sequence encoding an 18-mer peptide, or a functional equivalent thereof, to a gene encoding the protein and expressing the resultant gene-fusion product in an expression system. | 2009-01-08 |
| 20090011001 | Manufacturing process for liposomal preparations - The present invention provides a manufacturing process for liposomal preparations comprising water-insoluble or hydrophobic active principals. In accordance with one aspect of the inventive method, at least one active principal and lipid fraction are dissolved in an organic solvent. This solution is then subjected to reduced pressure (vacuum) in a container with or with out inert packing to remove the organic solvent, thereby forming a puffy cake comprising the active principal or principals and lipid fraction. This puffy cake is then mixed with an aqueous solution, under controlled conditions suitable to form a bulk liposomal preparation. Because the active principal is imbedded in the lipid bilayer, removal of the aqueous solution is optional. | 2009-01-08 |
| 20090011002 | Nano - and Mesosized Particles Comprising an Inorganic Core, Process and Applications Thereof - Method for the preparation of nano- and mesosized particles consisting of a lipid layer comprising at least one amphiphile and a core of an inorganic compound and/or a metal, comprising: (i) dissolving in a common solvent at least one self-aggregating amphiphile with at least one inorganic, organometallic or metallorganic precursor of said inorganic compound or metal; and (ii) either injecting the resulting solution into an aqueous solution or drying the resulting solution and re-hydrating it, so as to form particles in which the precursor is encapsulated by the amphiphile(s) and is converted therein to said inorganic compound and/or metallic solid form. | 2009-01-08 |
| 20090011003 | Composition for Suppressing Expression of Target Gene - The present invention has its object to provide a composition for suppressing the expression of a target gene and the like, and provides a composition, comprising an RNA-encapsulated liposome which comprises complex particles comprising as constituent components a lead particle and an RNA comprising a sequence consisting of 15 to 30 contiguous nucleotides of a target gene mRNA and a sequence complementary to the sequence, and a lipid membrane for coating the complex particles, wherein constituent components of the lipid membrane can be solved in a polar organic solvent, and wherein the polar organic solvent can be contained in a liquid at such a concentration that the constituent components of the lipid membrane are dispersible and the complex particles are dispersible, and the like. | 2009-01-08 |
| 20090011004 | IMPROVED CARRIERS FOR DELIVERY OF NUCLEIC ACID AGENTS TO CELLS AND TISSUES - This invention relates to drug delivery and specifically to the preparation and use of functionalized carriers such as nanopolymers and nanovesicles for improved delivery of nucleic acid agents (NAA) to tissues and cells. These compounds have broad applicability for treating numerous diseases and disorders, including neurodegenerative and neuromuscular disorders. The concept encompasses preferably polymeric carriers for delivery of a class of oligonucleotides that modulate RNA splicing. | 2009-01-08 |
| 20090011005 | Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions - Pharmaceutical compositions containing nanomaterials useful for treating restenotic lesions, which comprise nanomaterials containing one or more antiproliferative agents for treatment of intra-stent restenotic lesions by means of a local infusion, providing the increase in adhesion, penetration, and diffusion of the nanomaterials that contain the antiproliferative active agent in the tissue responsible for the neointimal hyperplasia, are described. | 2009-01-08 |
| 20090011006 | Once daily formulations of tetracyclines - Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis. | 2009-01-08 |
| 20090011007 | Pharmaceutical Compositions Containing Mixtures of Polymers and Active Agents Poorly Soluble in Water - The invention relates to a pharmaceutical composition comprising a mixture of at least one cationic, water-soluble (meth)acrylate copolymer, at least one water-insoluble polymer and at least one active ingredient having a solubility in demineralized water of 3.3 g/l or less, characterized in that the water-insoluble polymer and the active ingredient are present in a ratio of at most 3.5 to 1 parts by weight, and the pharmaceutical composition has the property of releasing the active ingredient present in a medium buffered to pH 1.2 in dissolved form in a concentration which, after 2 hours at pH 1.2, corresponds to at least sixteen times the solubility value of the active ingredient alone at pH 1.2. | 2009-01-08 |
| 20090011008 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery. | 2009-01-08 |
| 20090011009 | Microspheres comprising nanocapsules containing a lipophilic drug - The present invention provides microspheres comprising a plurality of nanocapsules accommodated in a gel forming polymer, the plurality of nanocapsules comprising an oil core carrying a non hydrophilic active agent and a shell of polymeric coating. The invention also provides a method for preparing the microspheres of the invention, pharmaceutical compositions comprising the same as well as methods of use of the microspheres, specifically, in therapeutic, cosmetic and diagnostic applications. | 2009-01-08 |
